MedTrace Logo

Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabetes

NCT01637935 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 193099

Last updated 2018-03-07

Study results available
· View outcomes & findings →

Summary

To assess the potential association between pioglitazone and bladder cancer compared with non-pioglitazone users among patients with type 2 diabetes mellitus.

Conditions

Interventions

DRUG

Pioglitazone

Pioglitazone tablets.

Sponsors & Collaborators

  • Kaiser Permanente

    collaborator OTHER

  • Department of Epidemiology at University of Pennsylvania

    collaborator UNKNOWN

  • Takeda

    lead INDUSTRY

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2014-08-31
Completion
2014-08-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01637935 on ClinicalTrials.gov